QUOTE AND NEWS
Motley Fool  Oct 21  Comment 
It's not a good sign that MannKind's competitor can't IPO.
SeekingAlpha  Oct 18  Comment 
By The Kumquat: Shout-out and Introduction This article was suggested by User 14219752. Although he said I should do 10 applications, I decided 10 would be too many, but thank you for the suggestion nonetheless. If you want to request an...
SeekingAlpha  Oct 14  Comment 
By George Rho: The shares of MannKind Corporation (NASDAQ:MNKD) have been in a virtual free-fall since hitting a seven-year high of $11.48 on June 30th. Incredibly, they are now at price levels seen before the company's flagship product Afrezza...
SeekingAlpha  Oct 14  Comment 
By The Kumquat: Introduction When an investor hears someone mention MannKind (NASDAQ:MNKD), the first thing that probably pops into his or her head is Afrezza, MNKD's inhaled insulin drug. While Afrezza is definitely a novel drug that has the...
SeekingAlpha  Oct 8  Comment 
By The Kumquat: Background (For those of you who already know all there is to know about MannKind (NASDAQ:MNKD), you can skip the background section and go to the analysis section.) Shares in biotechnology company MannKind have been on a...
Motley Fool  Oct 6  Comment 
Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?
SeekingAlpha  Oct 2  Comment 
By Looking For Diogenes: On April 1st, 2014, MannKind (NASDAQ:MNKD) had a favorable Adcom meeting where the committee members gave overwhelming support for the approval of Afrezza. MannKind's stock was halted the entire day of April 1st,...
StreetInsider.com  Sep 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/MannKind+%28MNKD%29+Enters+Revolving+Note%2C+Security+Agreement+with+Aventisub/9866300.html for the full story.
SeekingAlpha  Sep 26  Comment 
By Grant Wilson: MannKind's (NASDAQ:MNKD) diabetes drug Afrezza has the potential to steal a lot of share in a growing market. Insulin user growth has outpaced the growth of those diagnosed over the past 5 years - a trend that is likely to...
Reuters  Sep 25  Comment 
MannKind Corp shares were among the most actively traded in premarket on Thursday, after the company said it had closed a licensing agreement with Sanofi for the development and commercialization of its inhaled insulin product.




 

MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.

Competition

MannKind's primary competitors include:

References

  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki